Severe hypersensitivity pneumonitis associated with everolimus therapy for neuroendocrine tumour: A case report

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Sibertin Blanc, Camille ^a   Norguet, Emmanuelle ^a   Duluc, Muriel ^a   Louis, Guillaume ^a   Seitz, Jean François ^a   Dahan, Laetitia ^a,b  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b TIMONE HOSPITAL   (France)

Author keywords

Everolimus; Hypersensitivity pneumonitis; Neuroendocrine tumor

Indexed keywords

MAMMALIA;

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EVEROLIMUS; RAPAMYCIN;

ALLERGIC PNEUMONITIS; ARTICLE; CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; HUMAN; LIVER TUMOR; MALE; METASTASIS; MIDDLE AGED; NEUROENDOCRINE TUMOR; PATHOLOGY; SMALL INTESTINE;

ALVEOLITIS, EXTRINSIC ALLERGIC; ANTINEOPLASTIC AGENTS; HUMANS; INTESTINE, SMALL; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEUROENDOCRINE TUMORS; SIROLIMUS;

EID: 84887722469     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-471     Document Type: Article

References (12)

1. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. Missiaglia E, Dalai I, Barbi S, J Clin Oncol 2010 28 2 245 255 10.1200/JCO.2008.21.5988 19917848
2. Current development of mTOR inhibitors as anticancer agents. Faivre S, Kroemer G, Raymond E, Nat Rev Drug Disc 2006 5 671 688 10.1038/nrd2062 (Pubitemid 44151605)
3. A randomized double blind, placebo-controlled multicenter phase III trial of everolimus plus octreotide LAR vs placebo plus Octreotide LAR in patients with advanced neuroendocrine tumors (Radiant-2). Pavel M, Hainsworth JD, Baudin E, Eur J Cancer 2010 LBA8
4. RAD001 In advanced neuroendocrine tumors, third trial (RADIANT-3) study group. Yao JC, Shah MH, Ito T, Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011 364 6 514 523
5. Noninfectious pneumonitis after everolimus therapy for advanced renal cell carcinoma. White DA, Camus P, Endo M, Am J Respir Crit Care Med 2010 182 3 396 403 10.1164/rccm.200911-1720OC 20194812
6. Characterization of pneumonitis in patients with advanced non-small cell lung cancer treated with everolimus (RAD001). White DA, Schwartz LH, Dimitrijevic S, J Thorac Oncol 2009 4 11 1357 1363 10.1097/JTO.0b013e3181ba20b1 19745764
7. Pneumonitis associated with mammalian target of rapamycin inhibitors in renal transplant recipients: a single-center experience. Errasti P, Izquierdo D, Martín P, Transplant Proc 2010 42 8 3053 3054 10.1016/j.transproceed. 2010.07.066 20970608
8. Sirolimus and everolimus induced pneumonitis in adult renal allograft recipients: experience in a center. Rodríguez-Moreno A, Ridao N, García-Ledesma P, Transplant Proc 2009 41 6 2163 2165 10.1016/j.transproceed.2009.06.003 19715862
9. Everolimus-associated pneumonitis in 3 heart transplant recipients. Otton J, Hayward CS, Keogh AM, J Heart Lung Transplant 2009 28 1 104 106 10.1016/j.healun.2008.10.003 19134540
10. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Sánchez-Fructuoso AI, Ruiz JC, Pérez-Flores I, Transplant Proc 2010 42 8 3050 3052 10.1016/j. transproceed.2010.07.083 20970607
11. Severe everolimus-associated pneumonitis in a renal transplant recipient. Alexandru S, Ortiz A, Baldovi S, Nephrol Dial Transplant 2008 23 10 3353 3355 10.1093/ndt/gfn401 18658177
12. Everolimus-related pulmonary toxicity in heart transplant recipients. Expósito V, de Prada JA, Gómez-Román JJ, J Heart Lung Transplant 2008 27 7 797 800 10.1016/j.healun.2008.03.016 18582812